Structure Therapeutics (NASDAQ:GPCR) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Structure Therapeutics (NASDAQ:GPCR) from a sell rating to a hold rating in a report released on Saturday.

GPCR has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Structure Therapeutics in a report on Friday, November 28th. Jefferies Financial Group set a $125.00 target price on Structure Therapeutics in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Stifel Nicolaus upped their price objective on Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Finally, Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $95.78.

Structure Therapeutics Trading Down 0.6%

Structure Therapeutics stock opened at $67.06 on Friday. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $94.90. The company has a market capitalization of $3.88 billion, a PE ratio of -54.97 and a beta of -1.64. The stock has a 50-day moving average price of $35.52 and a two-hundred day moving average price of $25.81.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). As a group, analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of GPCR. State of Wyoming purchased a new position in shares of Structure Therapeutics during the 2nd quarter valued at about $28,000. EverSource Wealth Advisors LLC increased its position in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares during the last quarter. National Bank of Canada FI lifted its holdings in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after acquiring an additional 2,766 shares during the last quarter. Assetmark Inc. raised its holdings in Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares during the period. Finally, PNC Financial Services Group Inc. grew its holdings in Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.